融资方面，海思科当日融资买入1489.42万元。当前融资余额6837.94万元，占流通市值的0.13%，融资 余额超过近一年80%分位水平，处于高位。 2月3日，海思科跌5.47%，成交额4.30亿元。两融数据显示，当日海思科获融资买入额1489.42万元，融 资偿还1357.27万元，融资净买入132.15万元。截至2月3日，海思科融资融券余额合计7517.19万元。 融券方面，海思科2月3日融券偿还900.00股，融券卖出1300.00股，按当日收盘价计算，卖出金额6.17万 元；融券余量14.30万股，融券余额679.25万元，低于近一年20%分位水平，处于低位。 资料显示，海思科医药集团股份有限公司位于西藏山南市泽当镇三湘大道17号，成立日期2005年8月26 日，上市日期2012年1月17日，公司主营业务涉及化学药品的研究开发、生产制造、销售推广。主营业 务收入构成为：麻醉产品39.81%，合作产品相关收入23.59%，其他适应症17.02%，肠外营养系 10.32%，肿瘤止吐8.15%，其他(补充)0.86%，其他主营业务收入0.26%。 截至9月30日，海思科股东户数1.29万，较上期增加12. ...

Group 1 - Core viewpoint: Companies are announcing significant financial updates, including profit changes, new product approvals, and share repurchase plans [1][2][3][4][5][6][15] Group 2 - Company: Chip导科技 reported a revenue of 394 million yuan for 2025, a year-on-year increase of 11.52%, but a net profit of 106 million yuan, down 4.91% [1] - Company: 亿帆医药's subsidiary received a drug registration certificate for Vitamin K1 injection, which is used for treating vitamin K deficiency [2] - Company: 勤上股份 announced the termination of its share repurchase plan to stabilize stock prices [3] - Company: 极米科技 plans to repurchase shares worth between 50 million and 100 million yuan for employee stock ownership plans [4] - Company: 凌云光 intends to change the purpose of repurchased shares to cancellation, reducing total share capital from 461 million to 457 million shares [5] - Company: 苏州科达's general manager resigned, and the chairman will take over the role to ensure management continuity [6] - Company: 银轮股份 identified 徐铮铮 as a co-actual controller, following a retrospective recognition [7] - Company: 西南证券 received approval to issue bonds up to 14 billion yuan [8] - Company: 上港集团 expects a 1.3% year-on-year increase in container throughput for January [10] - Company: 宁波富达 plans to distribute a cash dividend of 0.7 yuan per 10 shares, totaling 101 million yuan [11] - Company: 协和电子 is investing 5 million yuan in a venture capital fund to enhance its understanding of high-tech industries [12] - Company: 乐鑫科技's controlling shareholder proposed a share repurchase plan of 50 million to 100 million yuan [13] - Company: 奥瑞德's subsidiary plans to invest approximately 145 million yuan in computing power equipment [14] - Company: 上汽集团 reported a 23.94% year-on-year increase in vehicle sales for January [15] - Company: 道恩股份 plans to acquire a foreign company's plastic business for 15.737 million USD [16] - Company: 红相股份 intends to transfer 100% equity of 南通瀚蓝 for 120 million yuan [17] - Company: 长龄液压 announced a tender offer to acquire 12% of its shares at 35.82 yuan per share [19] - Company: 润都股份 faces uncertainty regarding the approval of its innovative drug [20] - Company: *ST东易's asset injection plans face significant uncertainty [21] - Company: 棒杰股份 is undergoing a restructuring process that could improve its financial structure [22] - Company: 绿联科技 has submitted an application for H-share listing in Hong Kong [23] - Company: ST泉为 is facing a creditor's application for restructuring [24] - Company: 海思科's shareholders plan to reduce their holdings by up to 0.89% [25] - Company: 钧崴电子's shareholder plans to reduce holdings by up to 3% [26]

数据显示，摩根基金旗下1只基金重仓海思科。摩根医疗健康股票A（001766）四季度持有股数53.88万 股，占基金净值比例为6.04%，位居第七大重仓股。根据测算，今日浮亏损失约157.32万元。 2月3日，海思科跌5.81%，截至发稿，报47.33元/股，成交7384.70万元，换手率0.31%，总市值530.06亿 元。 资料显示，海思科医药集团股份有限公司位于西藏山南市泽当镇三湘大道17号，成立日期2005年8月26 日，上市日期2012年1月17日，公司主营业务涉及化学药品的研究开发、生产制造、销售推广。主营业 务收入构成为：麻醉产品39.81%，合作产品相关收入23.59%，其他适应症17.02%，肠外营养系 10.32%，肿瘤止吐8.15%，其他(补充)0.86%，其他主营业务收入0.26%。 从基金十大重仓股角度 截至发稿，叶敏累计任职时间3年193天，现任基金资产总规模16.45亿元，任职期间最佳基金回报 48.26%， 任职期间最差基金回报2.38%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本 文出现的信息均只作为参考，不构成个人投资建议。如 ...

Core Viewpoint - The announcement details a share reduction plan by significant shareholders of Haishike Pharmaceutical Group Co., Ltd., indicating a total potential reduction of up to 10,000,000 shares, which is approximately 0.89% of the company's total share capital [2][3]. Group 1: Shareholder Information - Shareholder Hao Congmei holds 3,518,000 shares, representing 0.31% of the total share capital, while shareholder Yang Fei holds 42,442,286 shares, representing 3.79% of the total share capital [2]. - The reduction plan involves Hao Congmei planning to reduce up to 2,000,000 shares (0.18% of total share capital) and Yang Fei planning to reduce up to 8,000,000 shares (0.71% of total share capital) [3]. Group 2: Reduction Plan Details - The reduction will occur within three months following a 15 trading day period after the announcement, using block trades or centralized bidding [2][3]. - The reason for the reduction is stated as personal funding needs [3]. - The shares to be reduced were originally acquired through block trades in 2015 [3]. Group 3: Compliance and Commitments - The shareholders have committed to avoiding any competition with the company's main business and ensuring that any related transactions are conducted fairly and transparently [5]. - The shareholders confirm that there are no circumstances that would prevent them from reducing their shares as per the regulations [5].

海思科2月2日公告，公司5%以上股东之一致行动人郝聪梅、杨飞计划自公告披露之日起15个交易日后 的3个月内，通过大宗交易或集中竞价方式减持公司股份合计不超过1000万股，即不超过公司总股本的 0.89%。其中郝聪梅拟减持不超过200万股，占公司总股本的0.18%；杨飞拟减持不超过800万股，占公 司总股本的0.71%。减持价格将根据减持时的市场价格确定，减持原因为个人资金需求。 ...

海思科（002653）(002653.SZ)发布公告，近日，公司收到部分5%以上股东之一致行动人郝聪梅女士、 杨飞女士《关于减持公司股份计划的告知函》，郝聪梅、杨飞计划自公告披露之日起十五个交易日后的 三个月内，通过大宗交易或集中竞价方式减持公司股份合计不超过1000万股，减持比例合计不超过公司 总股本的0.89%。 ...

Core Viewpoint - Haikang Pharmaceutical Group Co., Ltd. announced plans for significant share reductions by major shareholders, which may impact the stock's market performance [1] Shareholder Information - Shareholder Ms. Hao Congmei holds 3,518,000 shares, representing 0.31% of the total share capital [1] - Shareholder Ms. Yang Fei holds 42,442,286 shares, representing 3.79% of the total share capital [1] Planned Share Reduction - Ms. Hao Congmei and Ms. Yang Fei plan to reduce their holdings by a total of up to 10,000,000 shares, which is 0.89% of the total share capital, within three months after the announcement [1] - Ms. Hao Congmei intends to reduce her shares by no more than 2,000,000 shares, equating to 0.18% of the total share capital [1] - Ms. Yang Fei plans to reduce her shares by no more than 8,000,000 shares, which is 0.71% of the total share capital [1]

智通财经APP讯，海思科(002653.SZ)发布公告，近日，公司收到部分5%以上股东之一致行动人郝聪梅 女士、杨飞女士《关于减持公司股份计划的告知函》，郝聪梅、杨飞计划自公告披露之日起十五个交易 日后的三个月内，通过大宗交易或集中竞价方式减持公司股份合计不超过1000万股，减持比例合计不超 过公司总股本的0.89%。 ...

海思科公告，公司股东郝聪梅、杨飞计划15个交易日后的3个月内，通过大宗交易或集中竞价方式减持 公司股份合计不超过1000万股，减持比例合计不超过公司总股本的0.89%。 （文章来源：第一财经） ...

证券代码：002653 证券简称：海思科 公告编号：2026-015 海思科医药集团股份有限公司 关于部分 5%以上股东之一致行动人 股份减持计划的预披露公告 股东郝聪梅、杨飞保证向公司提供的信息披露内容的真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信 息一致。 特别提示： 截止本公告披露日，海思科医药集团股份有限公司（以下简称"公司"）股 东郝聪梅女士（5%以上股东郑伟之配偶）持有公司股份 3,518,000 股，占公司总 股本的 0.31%；股东杨飞女士（5%以上股东范秀莲之女）持有公司股份 42,442,286 股，占公司总股本的 3.79%。 一、本次减持主体及其一致行动人的持股情况 1 | 股东名称 | 持有股份数量（股） | 占公司总股本比例(%) | | --- | --- | --- | | 郝聪梅 | 3,518,000 | 0.31 | | 郑伟（5%以上股东） | 154,128,300 | 13.76 | | 合计 | 157,646,300 | 14.07 | | 股东名称 | 持有股份数量（股） | 占公司总股本 ...